NINDS study of aspirin v. ticlopidine in stroke prevention to begin patient accrual.
This article was originally published in The Tan Sheet
Executive Summary
NINDS STUDY COMPARING ASPIRIN WITH TICLOPIDINE IN STROKE PREVENTION in African Americans is expected to begin patient accrual in early November. The study, comparing aspirin with ticlopidine (Roche/Syntex' Ticlid) for recurrent stroke prevention, will be conducted under the direction of researchers at The Rush-Presbyterian-St. Luke's Medical Center in Chicago. The five-year, $10.8 mil. study is funded by a grant from the National Institute of Neurological Disorders & Stroke.
You may also be interested in...
Aspirin Better Than Ticlopidine For Stroke Recurrence Prevention In Blacks
Aspirin appears to be a "better treatment for aspirin-tolerant black patients with noncardioembolic ischemic stroke" than ticlopidine (Roche's Ticlid) for prevention of recurrent stroke, myocardial infarction and vascular death, according to a recent study
Aspirin Better Than Ticlopidine For Stroke Recurrence Prevention In Blacks
Aspirin appears to be a "better treatment for aspirin-tolerant black patients with noncardioembolic ischemic stroke" than ticlopidine (Roche's Ticlid) for prevention of recurrent stroke, myocardial infarction and vascular death, according to a recent study
Aspirin Better Than Ticlopidine For Stroke Recurrence Prevention In Blacks
Aspirin appears to be a "better treatment for aspirin-tolerant black patients with noncardioembolic ischemic stroke" than ticlopidine (Roche's Ticlid) for prevention of recurrent stroke, myocardial infarction and vascular death, according to a recent study